Login to Your Account

Trimeris, Roche's First-In-Class HIV Drug, Fuzeon, Approved

By Kim Coghill

Monday, March 17, 2003
The FDA cleared the accelerated approval application for Fuzeon, a first-in-class fusion inhibitor for HIV-1 developed by Trimeris Inc., and partner F. Hoffmann-La Roche Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription